AGTR1 and Marfan syndrome: While losartan effectively reduces the progression of aortic aneurysm in Marfan syndrome by blocking AGTR1 and inhibiting TGF-beta signaling, it has been proven that losartan does not improve the biomechanical integrity of the thoracic aorta in the vEDS mouse model [17,18].